MLYS Mineralys Therapeutics, Inc.
Healthcare$29.99+0.47%ClosedMarket Cap: $1.99B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.87
P/S
0.00
EV/EBITDA
-11.16
DCF Value
$2.53
FCF Yield
-6.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.9%
ROA
-23.2%
ROIC
-26.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-45.3M | $-39.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-38.3M | $-32.2M | $— | — |
| FY null | $0.00 | NaN% | $-170.6M | $-154.7M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-41.1M | $-36.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-46.7M | $-43.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-44.4M | $-42.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-51.8M | $-48.9M | $— | — |
| FY null | $0.00 | NaN% | $-192.4M | $-177.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-60.1M | $-56.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-45.2M | $-41.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-35.4M | $-31.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-27.7M | $-24.4M | $-0.61 | — |